The US Food and Drug Administration (FDA) has approved 14 new molecular entities (NMEs) thus far in 2019, behind the pace of last year’s record-setting 59 NME approvals. Which drugs…
Mid-Year Review: The Top 10 Pharma Deals of 2019 Thus Far
What have been the key deals among pharmaceutical companies thus far in 2019? From pending mega mergers of Bristol-Myers Squibb and Celgene and AbbVie and Allergan to Gilead’s large-scale R&D…
Whether on the “buy” or “sell” side, using the right negotiation tools and strategies is crucial. In DCAT Sharp Sourcing LIVE, a webinar from DCAT livestreamed from London, Niro Sivanathan,…
Pharma Industry Weighs in on Continuous Manufacturing
The pharma industry is providing feedback on the FDA’s draft guidance on continuous manufacturing, with GSK, Eli Lilly, AstraZeneca, J&J, the Association for Accessible Medicines, CEFIC’s Active Pharmaceutical Ingredients Committee,…
Pfizer’s CEO Makes Large Strategic Play in Oncology
Albert Bourla, who became CEO of Pfizer in January, has made his first large-scale deal as CEO: a pending $11.4-billion acquisition of Array BioPharma, which specializes in small-molecule cancer drugs.…
Executive Changes: What is Ahead for Sanofi’s New CEO
Sanofi CEO Olivier Brandicourt has announced plans to retire, effective September 1, with Paul Hudson, head of Novartis’ pharmaceutical division, taking the helm. With Sanofi facing competition in its diabetes-drug…
The pharmaceutical industry is in a wait-and-see mode as the UK tries to come up with a new Brexit plan that will mend internal division in the UK while still…
FDA’s New Acting Commissioner: What is In Store for the Agency?
Norman Sharpless, MD, became Acting Commissioner of Food and Drugs for the US Food and Drug Administration (FDA) in early April after taking the helm from FDA Commissioner Scott Gottlieb,…
Industry Roundtable: What’s Trending in Biomanufacturing
Biologics’ share in the industry’s pipeline and in the global pharmaceutical market is increasing, so what are the key issues shaping the current and future direction of biomanufacturing? Industry experts…
The $62-Billion Marriage of Shire and Takeda: The Risks and Rewards
Having completed its $62-billion acquisition of Shire earlier this month (January 2019), Takeda President and CEO Christopher Weber will now lead a new Top 10 pharma company with annual revenues…
